← All trials
NCT05753215
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 9, 2023
- Primary completion
- May 31, 2025
- Completion date
- Sep 30, 2025
- First posted
- Mar 3, 2023
- Last posted
- Nov 24, 2023
- Enrollment
- 180
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of California, Los AngelesLead sponsor
- University of California, Los AngelesReponsible party - principal investigator
- Paratek Pharmaceuticals IncCollaborator
- University of California, Los AngelesOverall official - principal investigator
- University of California, Los AngelesSponsor investigator
- University of California, Los AngelesOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.